B cell aplasia and hypogammaglobulinemia associated with levetiracetam
Küçük Resim Yok
Tarih
2018
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
K Faisal Spec Hosp Res Centre
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Levetiracetam (LEV) is a second-generation antiepileptic drug approved for the treatment of several types of epilepsy. We report a 45-year-old female who developed hypogammaglobulinemia and B cell aplasia during LEV treatment. The Naranjo probability score for an adverse drug reaction was 6. After LEV discontinuation, the number of B cells gradually increased and reached normal levels within two months. This case suggests that monitoring of immunoglobulin levels and lymphocyte subsets analysis is important in patients treated with LEV, especially in cases of prolonged infections.
Açıklama
Anahtar Kelimeler
[Keyword Not Available]
Kaynak
Annals Of Saudi Medicine
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
38
Sayı
1
